Key Highlights

  • SomnoMed Ltd (ASX:SOM) shares closed at $0.27 on 21 October 2026, up 14.89%.
  • FY26 revenue was $114.5 million (up 3%) and EBITDA was $10.9 million (up 19%), with net cash of $16.8 million.
  • The company is targeting high single-digit revenue growth in FY27 with EBITDA margins consistent with FY26.

SomnoMed Limited (ASX:SOM) shares gained 14.89% to close at $0.27 in the trading session on 21 October 2026, while the S&P/ASX 200 (XJO) stood at 8,809.20, down 7.70 points or 0.087%. SomnoMed provides oral appliance treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea (OSA).

What SomnoMed does

SomnoMed designs and manufactures oral appliance therapy devices that are used to treat obstructive sleep apnea and other sleep-related breathing disorders. Roughly 95% of its revenue is earned in currencies other than the Australian dollar, with Europe, North America and Asia Pacific its main regions.

The company has expanded its manufacturing capacity by more than 20% during FY26, and by more than 40% over two years, and reported that production times have been reduced by more than 50% over the same period.

FY26 results: financial summary

Separately from the day’s trading, SomnoMed’s FY26 full year results announcement dated 28 August 2026 is outlined below. Revenue for the year ended 30 June 2026 was $114.5 million, up 3% on the prior corresponding period, and EBITDA was $10.9 million, up 19% from $9.2 million. EBITDA margin rose 140 basis points to 9.6% from 8.2%.

Operating cash flow after lease expenses increased from $4.8 million to $5.2 million, and capital expenditure rose to $5.7 million from $4.0 million. Cash was $17.2 million, flat on the prior year, while debt reduced by 48% to $0.4 million, giving a net cash position of $16.8 million. The company noted that a change in European market dynamics and appreciation of the Australian dollar in the second half affected revenue growth: a decline of less than 1% in second-half revenue on a constant currency basis became a 7% reported decline in Australian dollars.

Regional revenue

Europe, the largest region, contributed $61.9 million, up 1% on a reported basis but down 1% in constant currency, with the company citing changes to clinical eligibility, public payor reimbursement criteria and patient referral pathways in the second half. North America contributed $45.8 million, up 6% reported and 11% in constant currency. Asia Pacific contributed $6.8 million, down 3%, with cost-of-living pressures affecting non-reimbursed markets.

Manufacturing and product innovation

SomnoMed added milling machines and made broader facility upgrades to lift manufacturing capacity, which the company said reduced reliance on overtime, eliminated order backlog and created capacity to support future growth. The company is evolving its portfolio to address differing reimbursement structures, clinical needs and market dynamics across its key regions.

A large-scale study published in 2023 and referenced in the announcement found that sleep bruxism affects about 50% of adults with OSA, which is the background to Virtus. The company reported initial feedback from participating clinicians on the clinical need and commercial opportunity.

Products, leadership and outlook

In late July 2026, SomnoMed began a controlled market release of Virtus, a therapy for patients with OSA and co-existing sleep bruxism, across North America, Europe and Asia Pacific. It is also evaluating an in-market US commercial assessment of Rest Assure under an existing FDA clearance during FY27.

Karen Borg is Chief Executive Officer following the late-July 2026 transition from co-CEO leadership, Greg Knight has been appointed Chief Operating Officer and Nathan Minnich Chief Marketing Officer. For FY27, the company is targeting high single-digit revenue growth with EBITDA margins consistent with FY26, with a guidance range to be issued at its 2026 Annual General Meeting, and has stated a longer-term target of a return to double-digit revenue growth.

In Europe, SomnoMed has reorganised its commercial, administrative and operational leadership, expanded its in-market presence in the first quarter of FY27 and is progressing engagement with larger clinics and dental groups, reimbursement evidence generation and sales force effectiveness initiatives. The company also said it would consider selective small-scale acquisitions where they complement its roadmap.

Sector context

Oral appliance therapy is one of several treatment pathways for obstructive sleep apnea, alongside continuous positive airway pressure (CPAP) therapy. SomnoMed has cited continued CPAP discontinuation rates, increasing OSA awareness linked to GLP-1 medicines and growth in home-based diagnostics as factors that may increase the number of patients seeking alternatives. Reimbursement rules, which vary by country, influence patient access to oral appliance therapies.

Risks and uncertainties

The company reported second-half revenue declines in reported terms and noted that European market conditions slowed patient access to oral appliances. As about 95% of revenue is in non-Australian currencies, exchange rate movements affect reported results. FY27 assumptions include continued growth in North America, European stabilisation and adoption of Virtus in the second half, and any of these may not eventuate. Capital expenditure increased during FY26, and the company’s FY27 guidance range is yet to be issued.

What’s next

SomnoMed expects to detail its strategic roadmap and issue its FY27 guidance range at the 2026 Annual General Meeting. Priorities include global commercialisation of Virtus, expanded in-market presence in Europe, reimbursement evidence generation and continued growth in North America.